MAIA Biotechnology, Inc.

AMEX:MAIA

Biotechnology

Healthcare
$1.30 +3.41%

+$0.05 today

Market cap
$80.28M
Beta
0.24
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.87High $3.19

Volume 2.25M

Average 0.78M

MAIA Net Income

Bottom-line profit after all expenses, interest, and taxes.

MAIA Biotechnology, Inc.AMEX: MAIA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$6.37M, compared with -$4.52M a year earlier. Trailing-twelve-month net income was -$24.25M.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$16.7M (+25.4%) for the fiscal year ending Dec 2026, a step up from the +3.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.37M-75.5% QoQ
Last fiscal yearDec 2025
-$22.4M+3.7% YoY
LTMMar 2026
-$24.25M-23.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-41.0%+33.9%+74.9 pp
1 year+3.7%+25.4%+21.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(22.4M) USD
Year-over-year change
+3.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How MAIA compares with its peers on the latest reported figures

  • MAIA's LTM Mar 2026 net income of -$24.25M is the 4th highest of the 7 companies compared; the peer median is -$24.77M.
  • Its year-over-year change of -23.1% is the 5th highest of 7, against a peer median of -14.9%.
MAIA Competitors Peer median
Net Income for MAIA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RNXTRenovoRx, Inc.LTM Mar 2026-$12.27M -20.8%—824.0%
VERUVeru Inc.LTM Mar 2026-$14.1M +61.2%——
LTRNLantern Pharma Inc.LTM Mar 2026-$15.91M +19.9%——
MAIAMAIA Biotechnology, Inc.LTM Mar 2026-$24.25M -23.1%——
PYPDPolyPid Ltd.LTM Mar 2026-$33.63M -9.0%——
ANVSAnnovis Bio, Inc.LTM Mar 2026-$40.92M -40.8%——
CELUCelularity Inc.LTM Dec 2025-$91.71M -58.4%—345.4%
Peer median (excluding MAIA) -$24.77M-14.9%—584.7%

Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development3.45M8.93M11.11M10.01M14.55B
Selling, General & Admin4.29M6.14M9.07M6.95M9.72B
Operating Expenses7.79M16.18M20.18M16.96M24.27M
Depreciation & Amortization00000
EBITDA(11.75M)(15.76M)(19.77M)(23.25M)(22.4M)
EBITDA Margin—————
Operating Income(7.79M)(16.18M)(20.18M)(16.96M)(24.27M)
Operating Margin—————
Interest Income2.01K1.87K27.63K318.37K313.95K
Interest Expense827.54K6.97K0570
Other Income / Expenses(4.79M)406.92K409.48K(6.3M)1.87M
Income Before Tax(12.58M)(15.77M)(19.77M)(23.25M)(22.4M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(12.5M)(15.77M)(19.77M)(23.25M)(22.4M)
Net Margin—————
EPS (Basic)(1.18)(1.70)(1.49)(1.05)(0.70)
EPS (Diluted)(1.18)(1.70)(1.49)(1.05)(0.70)
Weighted Avg Shares10.64M9.28M13.26M22.2M32.12M
Weighted Avg Shares (Diluted)10.64M9.28M13.26M22.2M32.12M

MAIA Biotechnology, Inc.

AMEX:MAIA

Intrinsic Alpha fair value

Locked

Current Price

$1.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.